Drug studies in Ontario, Canada, can now start in just 45 days through a study review pathway recently introduced by ...

Monthly insights, guidance alerts and blogs from global life sciences law firms, compiled for you in one place.

Conference Chair Adam Mostafa on why finance has become strategy for clinical-stage biotech from his insights at Finance and ...

Devin Smith is now Moderna’s chief ethics and compliance officer and head of legal. He brings over 25 years of legal ...

Susanne Michel, vice president, head of HTA methods and evidence planning at Clinigen, and Michael Epstein, vice president, ...

The legal experts recently discussed the mechanics of direct-to-patient (DTP) and direct-to-employer (DTE) models.

BioXconomy presents the Asia biopharma and healthcare dealmaking highlights for the week ending October 11, 2026.

The company has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 ...

Investor risk aversion was identified as the leading constraint on biotech investment, cited by 64% of respondents. In Europe ...

Pharma industry is navigating its biggest drug pricing compliance overhaul since 2006, as CMS’ 2026 Physician Fee Schedule ...

This investment hesitation represents more than financial calculations—it threatens the pipeline of future therapies. “The ...

Prader-Willi syndrome is a rare genetic condition that can present from birth. Its occurrence is around 1 in 15,000, and tens ...